Compare stocks
MRK vs BMY
| MRK Merck & Co., Inc. | BMY Bristol Myers Squibb Co | |
|---|---|---|
| Price | $145.95 | $59.75 |
| Sector | Health Care | Health Care |
| X-Ray Score | 32 | 59 |
| Valuation | 20 | 82 |
| Growth | 33 | 33 |
| Profitability | 44 | 58 |
| Financial health | 21 | 57 |
| Dividends | 56 | 55 |
| Fair value | $52 | $67 |
| Verdict | Overvalued -64% | Fair +12% |
| Revenue (TTM) | $66.6B | $49.2B |
| Operating margin | 11.6% | 27.7% |
| Return on capital | 6.1% | 19.3% |
| Revenue growth (3y) | 3.1% | 1.4% |
| Free-cash-flow yield | 4.5% | 9.3% |
| Net debt / EBITDA | 6.1× | 2.0× |
| Dividend yield | 2.3% | 4.2% |
Scores and fair values are model estimates from SEC filings, ranked within each company's own sector, so scores of companies in different sectors are not directly comparable. Educational only, not financial advice.